Cancer and Immunotherapy · global
Two Antibodies Team Up to Activate T Cells: PSA Falls by Half in 11 of 15 Patients in Early Prostate Cancer Trial
Pasritamig and JNJ-9401 mobilize immune cells through two complementary signals, producing preliminary responses in patients who have received multiple lines of treatment. Whether improvements in blood markers in this small trial translate into longer survival will be tested in a Phase 3 study.
When prostate cancer continues to progress after multiple lines of treatment, getting immune cells to recognize and attack cancer cells again is a challenge that new therapies are seeking to overcome. On November 8, Johnson & Johnson announced an early human study: following treatment with two bispecific antibodies in combination, 11 of the 15 patients receiving the recommended regimen had a decline in prostate-specific antigen (PSA) of at least half. This provides evidence of anticancer activity, but does not yet establish that patients live longer as a result.
The Phase 1 trial, NCT06095089, enrolled patients with metastatic castration-resistant prostate cancer, and its results were presented at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting. As of June 15, the study had enrolled 144 patients overall; the focus of this report was the 15 receiving the recommended regimen, who had received a median of four prior lines of systemic therapy. The 73.3% PSA response rate therefore comes from this small group and cannot be applied to all participants.
The two drugs play different roles. Pasritamig binds both the prostate cancer-associated protein KLK2 and CD3 on T cells, directing immune cells toward cancer cells and providing an activation signal. JNJ-9401, also known as JNJ-87189401, binds PSMA on tumors and CD28 on T cells, supplying a costimulatory signal. This design aims to enhance T-cell activity while guiding the cells toward their targets.
There were also preliminary signs of deep responses: seven of the 15 patients had PSA declines of at least 90%. According to OncLive, four additional patients had PSA levels fall below 0.2 nanograms per milliliter; all four responses lasted more than six months and were ongoing at the data cutoff. However, PSA is a blood marker used to track disease activity; a substantial decline does not mean that tumors have disappeared on imaging, nor can it be directly translated into a survival benefit.
The dosing schedule consisted of two weekly step-up doses of pasritamig, followed by intravenous pasritamig 300 mg combined with subcutaneous JNJ-9401 200 mg every six weeks. Among these 15 patients, no Grade 3 or higher treatment-related adverse events were reported; three patients experienced cytokine release syndrome, all involving transient Grade 1 fever. These reactions arise from immune activation and are a risk that requires monitoring with this type of therapy.
Safety findings must still be interpreted within the limits of the doses and patient numbers studied. OncLive noted that across all dose groups, comprising 144 patients, the rate of Grade 3 or higher treatment-related adverse events was 12.5%; immune-mediated hepatitis also occurred at higher doses, with higher exposure, or with more frequent dosing. Thus, the absence of serious treatment-related toxicity so far in the recommended-regimen group remains insufficient to establish safety in a larger population or with long-term use.
The next key step is to assess these early responses in a comparative study. The ongoing Phase 3 KLK2-comPAS trial will evaluate pasritamig alone or with JNJ-9401, with overall survival as the primary endpoint. The Phase 1 results support continued investigation of this dual-signal strategy; whether it outperforms a single agent and can extend life remains to be answered by further data.